NCT01366001View on ClinicalTrials.gov

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Cocaine Abuse
Interventions
DRUG

ALKS 33-BUP

Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.

DRUG

ALKS 33

Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.

DRUG

Placebo

Sublingual administration, Placebo administered once daily for 10 consecutive days.

Trial Locations (1)

66212

Alkermes Study Site, Overland Park

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Alkermes, Inc.

INDUSTRY